



(51) International Patent Classification:

C07D 401/02 (2006.01) *A61K 31/437* (2006.01)
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/506 (2006.01)

(21) International Application Number:

PCT/GB2012/051783

(22) International Filing Date:

25 July 2012 (25.07.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/512,061 27 July 2011 (27.07.2011) US
 61/591,363 27 January 2012 (27.01.2012) US

(71) Applicant (for all designated States except BN, MG, US):
ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London, Greater London W2 6BD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUTTERWORTH, Sam** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **FINLAY,**


Maurice, Raymond, Verschoyle [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WARD, Richard, Andrew** [GB/GB]; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **KADAMBAR, Vasantha, Krishna** [IN/IN]; AstraZeneca India Private Limited, Hebbal, Off Bellary Road, Bangalore 560024 (IN). **CHANDRASHEKAR, Reddy, C.** [IN/IN]; AstraZeneca India Private Limited, Hebbal, Off Bellary Road, Bangalore 560024 (IN). **MURUGAN, Andiappan** [IN/IN]; AstraZeneca India Private Limited, Hebbal, Off Bellary Road, Bangalore 560024 (IN). **REDFEARN, Heather, Marie** [GB/GB]; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: 2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER



(57) Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))